Overview
- The peer‑reviewed Cell Metabolism paper from Toronto’s Sinai Health, published Tuesday, reports that semaglutide targets rare liver sinusoidal endothelial cells to cut inflammation and scarring without needing weight loss.
- Mice engineered to resist GLP‑1‑driven weight loss still showed liver healing, while mice missing the liver‑cell receptors saw no liver improvement even after losing about 20% of body weight.
- The researchers also detected GLP‑1 receptors on immune T cells and showed that the endothelial cells switch on genes that release anti‑inflammatory signals across the liver.
- Doctors say this mechanism could justify lower doses for liver disease and push insurers to drop strict weight‑loss cutoffs, offering options for the 10% to 15% of patients who do not lose much weight on GLP‑1 drugs.
- Experts note the work was done in mice and needs human proof, and regulators in Canada have already given Wegovy a conditional approval for MASH, a severe fatty liver disease marked by fat buildup, inflammation, and scarring.